TD Ameritrade Investment Management’s Aimmune Therapeutics AIMT Stock Holding History

TD Ameritrade Investment Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	–	–	748
2021 Q3	$0	Buy	+1	New	–	﹤0.01%	721
2020 Q4	–	Sell	-1	Closed	–	–	671
2020 Q3	$0	Buy	+1	New	+$21	﹤0.01%	667

TD Ameritrade Investment Management's AIMT Position: Q4 2021 in Review

TD Ameritrade Investment Management sold out of Aimmune Therapeutics (AIMT) in Q4 2021, closing a stake of 1 share.

TD Ameritrade Investment Management first reported a position in AIMT in Q3 2020 and held it in 2 quarters. The position peaked at $0 in Q3 2021. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2021.

TD Ameritrade Investment Management reported no remaining Aimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
TD Ameritrade Investment Management sold 1 Aimmune Therapeutics share in Q4 2021.
TD Ameritrade Investment Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 2 quarters.
TD Ameritrade Investment Management's Aimmune Therapeutics position peaked at $0 in Q3 2021.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2021.

Based on TD Ameritrade Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.